SCHEMBL5273629

SCHEMBL5273629

COC(=O)c1ccc(C)c(-c2ccc(C(=O)Nc3ccncc3C)s2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ IL2 P60568 4/20 1.00
▸ TP53 P04637 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ MAPK11 Q15759 11/20 0.47
▸ MAPK14 Q16539 11/20 0.47
▸ MAPK13 O15264 6/20 0.47
▸ MAPK12 P53778 6/20 0.47
▸ S1PR2 O95136 1/20 0.46
▸ S1PR4 O95977 1/20 0.46
▸ ROCK2 O75116 1/20 0.42
▸ GPBAR1 Q8TDU6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5274000 0.91 IL2 (0.83) IL2TP53SMN1; SMN2MAPK11MAPK14
SCHEMBL5268528 0.91 IL2 (0.83) IL2TP53SMN1; SMN2MAPK11MAPK14
SCHEMBL5270337 0.90 IL2 (0.82) IL2TP53SMN1; SMN2MAPK11MAPK14
SCHEMBL8261510 0.88 IL2 (0.79) IL2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5272414 0.88 IL2 (0.79) IL2MAPK11MAPK14MAPK13MAPK12
SCHEMBL8261507 0.83 IL2 (0.71) IL2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5268719 0.82 IL2 (0.70) IL2TP53SMN1; SMN2MAPK11MAPK14
SCHEMBL5274940 0.82 IL2 (0.69) IL2TP53SMN1; SMN2MAPK11MAPK14
SCHEMBL8262611 0.82 IL2 (0.69) IL2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5268631 0.81 IL2 (0.81) IL2TP53SMN1; SMN2MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802721-B2 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-08-12 — — US claimed
EP-1846388-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2007-10-24 — — EP claimed
US-20060199845-A1 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2006-09-07 — — US claimed
WO-2006081389-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2006-08-03 — — WO claimed
US-8802721-B2 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-08-12 — — US disclosed
US-8802721-B2 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-08-12 — — US disclosed
US-8802721-B2 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-08-12 — — US disclosed
EP-1846388-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2007-10-24 — — EP disclosed
US-20060199845-A1 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2006-09-07 — — US disclosed
WO-2006081389-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2006-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199845-A1 Thiophene compounds for inflammation and immune-related uses CXCR2, TPMT, CXCR1 IL2 40/4885TP53 486/4885SMN1; SMN2 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback